KIA
LGND icon

Kopp Investment Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Kopp Investment Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$1.05M Sell
16,957
-5,907
-26% -$371K 1.94% 18
2019
Q2 		$1.63M Sell
22,864
-7,899
-26% -$582K 1.85% 18
2019
Q1 		$2.41M Sell
30,763
-239
-0.8% -$18.1K 1.95% 20
2018
Q4 		$2.62M Sell
31,002
-220
-0.7% -$23.5K 2.56% 18
2018
Q3 		$5.35M Sell
31,222
-5,865
-16% -$884K 4.5% 7
2018
Q2 		$4.79M Buy
37,087
+2,775
+8% +$310K 4.5% 3
2018
Q1 		$3.54M Sell
34,312
-996
-3% -$98.5K 3.59% 4
2017
Q4 		$3.02M Sell
35,308
-32
-0.1% -$2.77K 3.02% 11
2017
Q3 		$3M Sell
35,340
-593
-2% -$47K 2.75% 13
2017
Q2 		$2.72M Sell
35,933
-1,840
-5% -$129K 2.44% 15
2017
Q1 		$2.49M Sell
37,773
-354
-0.9% -$23.3K 2.44% 14
2016
Q4 		$2.42M Buy
38,127
+524
+1% +$33.1K 2.55% 10
2016
Q3 		$2.39M Sell
37,603
-11,155
-23% -$819K 2.37% 14
2016
Q2 		$3.63M Sell
48,758
-1,150
-2% -$85.3K 1.93% 10
2016
Q1 		$3.33M Buy
49,908
+1,033
+2% +$62.8K 1.82% 11
2015
Q4 		$3.31M Sell
48,875
-1,632
-3% -$101K 1.63% 15
2015
Q3 		$2.7M Buy
50,507
+5,873
+13% +$356K 1.45% 17
2015
Q2 		$2.81M Buy
44,634
+5,359
+14% +$292K 1.25% 21
2015
Q1 		$1.89M Buy
39,275
+1,234
+3% +$47.3K 0.84% 28
2014
Q4 		$1.26M Buy
38,041
+8,597
+29% +$280K 0.61% 32
2014
Q3 		$863K Sell
29,444
-768
-3% -$25.5K 0.43% 48
2014
Q2 		$1.17M Buy
30,212
+22,178
+276% +$900K 0.54% 36
2014
Q1 		$337K Buy
8,034
+1,616
+25% +$67.4K 0.14% 58
2013
Q4 		$211K Sell
6,418
-62,734
-91% -$2.04M 0.1% 59
2013
Q3 		$1.87M Sell
69,152
-10,003
-13% -$281K 0.69% 31
2013
Q2 		$1.85M Buy
+79,155
New +$1.42M 0.72% 31

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Kopp Investment Advisors's LGND Position: Q3 2019 in Review

Kopp Investment Advisors reduced its Ligand Pharmaceuticals (LGND) stake by 26% in Q3 2019, selling an estimated $371K and leaving 16,957 shares worth $1.05M. The position accounts for 1.94% of the portfolio, ranked #18.

Kopp Investment Advisors first reported a position in LGND in Q2 2013 and has held it in 26 quarters since. The position peaked at $5.35M in Q3 2018. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

  • Kopp Investment Advisors held 16,957 shares of Ligand Pharmaceuticals worth $1.05M as of Q3 2019.
  • Kopp Investment Advisors sold 5,907 Ligand Pharmaceuticals shares in Q3 2019, an estimated $371K.
  • Ligand Pharmaceuticals made up 1.94% of Kopp Investment Advisors's portfolio in Q3 2019, its #18 holding.
  • Kopp Investment Advisors first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 26 quarters since.
  • Kopp Investment Advisors's Ligand Pharmaceuticals position peaked at $5.35M in Q3 2018.
  • 275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on Kopp Investment Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.